Overview

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Status:
Completed

Trial end date:
2017-03-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients with Acute Coronary Syndromes

Phase:

Phase 2

Details

Lead Sponsor:

Seung-Jung Park

Collaborators:

AstraZeneca
KBM pharm
Roche Pharma AG

Treatments:

Clopidogrel
Ticagrelor
Ticlopidine